^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) + Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
289MO - Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Published date:
11/27/2023
Excerpt:
Among tumor evaluable naïve and treated pts, confirmed ORR (cORR) were 50.0% (PR 3/6) and 29.6% (CR 1/27 and PR 7/27); median TTR were 2.7 and 3.1 mo; DCR were both 100%. In naïve (N=6) and treated (N=28) pts, mPFS were 10.3 and 8.2 mo, 15mo-OS rate were 83.3% and 70.0%. In tumor evaluable treated pts stratified by CPS ≥1 vs <1 (N= 17 vs 8), cORR was 41.2% vs 12.5%; in treated pts (N=18 vs 8), mPFS was 19.4 vs 5.2 mo...F plus S provided favorable efficacy in advanced CC pts, especially for treated PD-L1 CPS ≥1 pts.
Trial ID:
